Whale Analyzer
OrbiMed Advisors 13F Holdings and Portfolio Changes
OrbiMed Advisors reported $5.40B in 13F securities for Q2 2026, with 129 positions. Values are as of the report date; option positions, when present, use underlying-security values. This is not complete fund assets or investment performance.
Open interactive portfolioLatest 13F portfolio changes
New or increased positions include ELI LILLY & (LLY), ASTRAZENECA (AZN), STRUCTURE THERAPEUTICS (GPCR), and GUARDANT HEALTH (GH). Reduced or exited positions include ENLIVEN THERAPEUTICS (ELVN), MBX BIOSCIENCES (MBX), MYRIAD GENETICS, and SIONNA THERAPEUTICS (SION). These are comparisons between reported positions, not a record of execution dates, prices or cash traded.
Latest filing metadata: quarter Q2 2026; report date 2026-06-30; filing date 2026-08-14; disclosure source SEC 13F.
Reported holdings and concentration
OrbiMed Advisors's Q2 2026 13F report contains 129 positions valued at $5.40B. The largest reported holdings include EDGEWISE THERAPEUTICS, ENLIVEN THERAPEUTICS, ELI LILLY &, MBX BIOSCIENCES, and SINOVAC BIOTECH.
The three largest positions in the holdings table account for approximately 24.3% of reported 13F value. The largest reported sector exposure is Health Care at 79.7% of the disclosed portfolio.
The filing metadata lists report date 2026-06-30, filing date 2026-08-14, SEC accession 0001172661-26-003740. SEC 13F reports are normally published up to 45 days after quarter end, so the data is best used to understand institutional positioning after the fact rather than to infer today's exact portfolio.
OrbiMed Advisors portfolio analytics
the top five positions account for 31.7% of disclosed value; the largest sector exposure is Health Care at 79.7%; latest prices differ from modeled cost estimates by an average 194.9% across 116 tracked positions (estimated costs, not reported purchase prices or actual investment returns).
Top reported holdings
| Holding | Reported value | Weight | Quarter change |
|---|---|---|---|
| EWTX whale holders EDGEWISE THERAPEUTICS INC | $630.5M | 11.9% | Held |
| ELVN whale holders ENLIVEN THERAPEUTICS INC | $343.9M | 6.5% | Reduced |
| LLY whale holders ELI LILLY & CO | $309.3M | 5.9% | Increased |
| MBX whale holders MBX BIOSCIENCES INC | $189.3M | 3.6% | Reduced |
| SVA whale holders SINOVAC BIOTECH LTD | $184.5M | 3.5% | Held |
| AZN whale holders ASTRAZENECA PLC | $171.1M | 3.2% | Increased |
| GPCR whale holders STRUCTURE THERAPEUTICS INC | $118.6M | 2.2% | Increased |
| SION whale holders SIONNA THERAPEUTICS INC | $112.4M | 2.1% | Reduced |
| CRVS whale holders CORVUS PHARMACEUTICALS INC | $107.0M | 2.0% | Held |
| AVBP whale holders ARRIVENT BIOPHARMA INC | $105.2M | 2.0% | Held |
New and increased positions
Largest reported position values among additions; not amounts spent buying.
- LLY whale holders — ELI LILLY & CO ($309.3M)
- AZN whale holders — ASTRAZENECA PLC ($171.1M)
- GPCR whale holders — STRUCTURE THERAPEUTICS INC ($118.6M)
- GH whale holders — GUARDANT HEALTH INC ($87.6M)
- PRAX whale holders — PRAXIS PRECISION MEDICINES I ($77.0M)
- PRLD whale holders — PRELUDE THERAPEUTICS INC ($73.2M)
Reduced and exited positions
Sorted by reported position value; exits use the prior report. These are not sale proceeds.
- ELVN whale holders — ENLIVEN THERAPEUTICS INC ($343.9M)
- MBX whale holders — MBX BIOSCIENCES INC ($189.3M)
- N/A whale holders — MYRIAD GENETICS INC ($122.9M)
- SION whale holders — SIONNA THERAPEUTICS INC ($112.4M)
- ARGX whale holders — ARGENX SE ($86.2M)
- QURE whale holders — UNIQURE NV ($83.3M)
Allocation
- Health Care: 79.7%
- Other: 19.3%
Data notes
Report date: 2026-06-30
Disclosure source: SEC 13F
Read the original SEC filing (0001172661-26-003740)
SEC 13F filings are delayed public disclosures and do not include every asset class, short positions, or real-time trades.
Related investor portfolios
- Duquesne Family Office 13F holdings and portfolio changes — Duquesne Family Office
- Ruane, Cunniff & Goldfarb 13F holdings and portfolio changes — Ruane, Cunniff & Goldfarb
- Maverick Capital 13F holdings and portfolio changes — Maverick Capital
- Polen Capital Management 13F holdings and portfolio changes — Polen Capital Management
- Baker Bros. Advisors 13F holdings and portfolio changes — Baker Bros. Advisors
- Valley Forge Capital Management 13F holdings and portfolio changes — Valley Forge Capital Management
- Tiger Global Management 13F holdings and portfolio changes — Tiger Global Management
- ARK Investment Management 13F holdings and portfolio changes — ARK Investment Management
Learn more in Whale Analyzer Academy
Learn more in Whale Analyzer Academy:
Questions about this 13F filing
What does OrbiMed Advisors report for Q2 2026?
The filing reports 129 positions and $5.40B in 13F securities. The holdings table shows reported values and weights; option values follow the filing's reporting conventions.
What changed between filings?
New or increased positions include ELI LILLY & (LLY), ASTRAZENECA (AZN), STRUCTURE THERAPEUTICS (GPCR), and GUARDANT HEALTH (GH). Reduced or exited positions include ENLIVEN THERAPEUTICS (ELVN), MBX BIOSCIENCES (MBX), MYRIAD GENETICS, and SIONNA THERAPEUTICS (SION).
Do these amounts show how much was bought or sold?
No. The change lists are ranked by reported position value. Exited positions use their value in the prior report. These amounts are not execution prices, cash invested or sale proceeds.
Is this the current portfolio?
No. Form 13F is a quarter-end snapshot, generally filed within 45 days of quarter end. It excludes short positions and does not cover every asset. Compare the report date and filing date before using the data.